MA45222A - Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant - Google Patents

Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant

Info

Publication number
MA45222A
MA45222A MA045222A MA45222A MA45222A MA 45222 A MA45222 A MA 45222A MA 045222 A MA045222 A MA 045222A MA 45222 A MA45222 A MA 45222A MA 45222 A MA45222 A MA 45222A
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
piperidinyl derivatives
new piperidinyl
Prior art date
Application number
MA045222A
Other languages
English (en)
Other versions
MA45222B1 (fr
Inventor
Maïa Chanrion
Didier Demarles
Olivier Geneste
Árpád Kiss
András Kotschy
Elodie Lewkowicz
Alba Macias
Balázs Molnár
James Brooke Murray
Attila Vasas
Csaba Wéber
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA45222A publication Critical patent/MA45222A/fr
Publication of MA45222B1 publication Critical patent/MA45222B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de formule (i), r1, r2, r3, n et w étant tels que définis dans la description. L'invention concerne également des médicaments.
MA45222A 2016-06-10 2017-06-09 Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant MA45222B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655392A FR3052452B1 (fr) 2016-06-10 2016-06-10 Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2017/064067 WO2017212012A1 (fr) 2016-06-10 2017-06-09 Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
MA45222A true MA45222A (fr) 2019-04-17
MA45222B1 MA45222B1 (fr) 2020-04-30

Family

ID=56943687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45222A MA45222B1 (fr) 2016-06-10 2017-06-09 Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant

Country Status (45)

Country Link
US (1) US11046681B2 (fr)
EP (1) EP3468974B1 (fr)
JP (1) JP6928005B2 (fr)
KR (1) KR20190016106A (fr)
CN (1) CN109311888B (fr)
AR (1) AR108706A1 (fr)
AU (1) AU2017277734B2 (fr)
BR (1) BR112018075433A2 (fr)
CA (1) CA3027014C (fr)
CL (1) CL2018003474A1 (fr)
CO (1) CO2018013210A2 (fr)
CR (1) CR20180564A (fr)
CU (1) CU20180145A7 (fr)
CY (1) CY1122870T1 (fr)
DK (1) DK3468974T3 (fr)
DO (1) DOP2018000270A (fr)
EA (1) EA037211B1 (fr)
EC (1) ECSP18090144A (fr)
ES (1) ES2775789T3 (fr)
FR (1) FR3052452B1 (fr)
GE (1) GEP20207160B (fr)
HR (1) HRP20200361T1 (fr)
HU (1) HUE049507T2 (fr)
IL (1) IL263463B (fr)
LT (1) LT3468974T (fr)
MA (1) MA45222B1 (fr)
MD (1) MD3468974T2 (fr)
ME (1) ME03670B (fr)
MX (1) MX2018015216A (fr)
MY (1) MY196562A (fr)
NI (1) NI201800132A (fr)
PE (1) PE20220567A1 (fr)
PH (1) PH12018502515B1 (fr)
PL (1) PL3468974T3 (fr)
PT (1) PT3468974T (fr)
RS (1) RS60029B1 (fr)
RU (1) RU2743163C2 (fr)
SG (1) SG11201810629QA (fr)
SI (1) SI3468974T1 (fr)
SV (1) SV2018005791A (fr)
TN (1) TN2018000410A1 (fr)
TW (1) TWI620750B (fr)
UA (1) UA123794C2 (fr)
UY (1) UY37288A (fr)
WO (1) WO2017212012A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
AU2018254577B2 (en) 2017-04-21 2024-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
MX2020005500A (es) * 2017-11-29 2020-08-31 Servier Lab Derivados novedosos de piperidinilo como inhibidores de la proteasa 7 ubiquitina especifica.
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
BR112021005091A2 (pt) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
JP2022512128A (ja) * 2018-12-06 2022-02-02 アルマック・ディスカバリー・リミテッド 医薬化合物およびユビキチン特異的プロテアーゼ１９（ｕｓｐ１９）阻害剤としてのその使用
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (fr) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521445A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
MX2009009417A (es) * 2007-03-02 2009-09-11 Schering Corp Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
EP2565186A1 (fr) * 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
RU2742271C2 (ru) * 2016-06-10 2021-02-04 Ле Лаборатуар Сервье Новые (гетеро)арил-замещенные пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их

Also Published As

Publication number Publication date
FR3052452A1 (fr) 2017-12-15
LT3468974T (lt) 2020-04-10
RU2018147430A3 (fr) 2020-07-10
EA201892838A1 (ru) 2019-06-28
CA3027014C (fr) 2021-01-05
ECSP18090144A (es) 2019-01-31
GEP20207160B (en) 2020-10-12
MA45222B1 (fr) 2020-04-30
TWI620750B (zh) 2018-04-11
IL263463B (en) 2021-01-31
CO2018013210A2 (es) 2018-12-28
UA123794C2 (uk) 2021-06-02
IL263463A (en) 2019-01-31
JP6928005B2 (ja) 2021-09-01
SI3468974T1 (sl) 2020-07-31
CN109311888B (zh) 2021-09-14
DOP2018000270A (es) 2019-05-15
KR20190016106A (ko) 2019-02-15
UY37288A (es) 2018-01-02
NI201800132A (es) 2019-04-08
HRP20200361T1 (hr) 2020-06-12
TW201802092A (zh) 2018-01-16
PH12018502515A1 (en) 2019-09-30
ME03670B (fr) 2020-10-20
SV2018005791A (es) 2019-01-16
TN2018000410A1 (en) 2020-06-15
US20190144448A1 (en) 2019-05-16
RU2018147430A (ru) 2020-07-10
DK3468974T3 (da) 2020-05-11
MD3468974T2 (ro) 2020-05-31
PE20220567A1 (es) 2022-04-13
AU2017277734A1 (en) 2018-12-20
EP3468974B1 (fr) 2020-02-12
EP3468974A1 (fr) 2019-04-17
RU2743163C2 (ru) 2021-02-15
PH12018502515B1 (en) 2019-09-30
PT3468974T (pt) 2020-03-25
AR108706A1 (es) 2018-09-19
BR112018075433A2 (pt) 2019-03-19
MX2018015216A (es) 2019-04-25
CU20180145A7 (es) 2019-07-04
HUE049507T2 (hu) 2020-09-28
EA037211B1 (ru) 2021-02-19
SG11201810629QA (en) 2018-12-28
CA3027014A1 (fr) 2017-12-14
WO2017212012A1 (fr) 2017-12-14
FR3052452B1 (fr) 2018-06-22
US11046681B2 (en) 2021-06-29
CL2018003474A1 (es) 2019-05-24
AU2017277734B2 (en) 2021-07-01
CY1122870T1 (el) 2021-05-05
CN109311888A (zh) 2019-02-05
JP2019517556A (ja) 2019-06-24
ES2775789T3 (es) 2020-07-28
MY196562A (en) 2023-04-19
PL3468974T3 (pl) 2020-07-13
CR20180564A (es) 2019-03-04
RS60029B1 (sr) 2020-04-30

Similar Documents

Publication Publication Date Title
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA45223B1 (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA42232B1 (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA32941B1 (fr) Composes organiques
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA38138A1 (fr) Dérivés inédits de quinolone
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
TN2009000450A1 (fr) Derives de pyridine
MA43251B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA29926B1 (fr) Derives de pyrazine
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle